Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

View Metsera, Inc. MTSR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting effects than current weight loss treatments on the ...

Metsera said its drug’s half-life of 19 days supports once-monthly dosing. That would be an advantage over the once-weekly dosing of the GLP-1 drugs currently available and the clinical-stage ...

Investment Overview - Metsera Latest To Join Obesity Market Challengers. Obesity is forecast by some analysts to become a >$200bn market, with up to 16 new drugs on the market by 2031. Eli Lilly ...

Get the latest Metsera, Inc. (MTSR) stock news and headlines to help you in your trading and investing decisions.

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. And the company is ready to scale up. Published: Feb. 25, 2025 at 1:42 p.m. ET. Share.

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for ...

One of the big questions going into the phase I readout for Metsera Inc.’s amylin analogue, MET-233i, was whether findings would support once-monthly dosing for the potential obesity candidate. They ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin ...